LOXAM/JCDECAUX
28.3.2017 16:42:10 CEST | Business Wire | Press release
In 2017, LOXAM, the European leader in the rental of equipment and tooling for building, public works and industry, is celebrating its 50th anniversary. In association with JCDecaux Artvertising, a vast fresco produced by the agency SuperCafard has been installed on the glass façade of its Group Headquarters at Porte Maillot, Paris. Spanning almost 500 square metres, this specially-created visual represents the vitality that has been the Group’s hallmark over the past 50 years.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170328006023/en/
This year LOXAM is celebrating its 50th , and is keen to tell the world. Founded in Brittany in 1967, the Group is today the European number one in equipment rental. This outstanding achievement is shared by the 7,500 employees in the company today, spread over 21 countries around the world. To produce and deploy a visual in keeping with the scale of the event, LOXAM selected the agency SuperCafard to design the graphics, and JCDecaux Artvertising – its long-standing partner in temporary display advertising – for the installation of the decal on the façade of its Paris offices.
Capitalising on the expertise and experience of the teams at JCDecaux Artvertising, the decal measuring nearly 500 square metres was installed in the space of three days by six abseilers. Five spotlights are trained on this visual, which will now be visible to more than 50,000 vehicles per day passing through the Place de la Porte Maillot between now and the end of June.
An exceptional anniversary deserves exceptional visibility at LOXAM!
About :
JCDecaux Artvertising
With prestigious and strategically-located locations, the full range of JCDecaux Artvertising’s special-build decal solutions provides brands with powerful assets with which to promote their image.
LOXAM
Loxam is the market leader in the rental of equipment and tooling for
building, public works and industry, with pro forma turnover of 1.3
billion euros in 2016 and a workforce of 7,500 employees. The Group
operates out of 21 countries around the world.
www.loxam.com
SuperCafard
SuperCafard, an independently-owned design agency, is proud to support LOXAM in a BIG celebration. For the 50th anniversary of the equipment rental company, SuperCafard thought big by recommending a visual on the scale of a major brand. Just like LOXAM, we are not afraid to magnify major projects, and we will always find the means to embody them.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170328006023/en/
Contact:
LOXAM press contact
Yannick DUVERGE,
Tel.: +33 6
89 44 64 07
yannick@relationpresse.com
or
JCDecaux
product communication press contact
Xavier GUEPET,
Tel.:
+33 1 30 79 34 48
xavier.guepet@jcdecaux.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom